Complete financial analysis of Kymera Therapeutics, Inc. (KYMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kymera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hoteles City Express, S.A.B. de C.V. (HOCXF) Income Statement Analysis – Financial Results
- Central Pattana Public Company Limited (CPNNF) Income Statement Analysis – Financial Results
- Concord New Energy Group Limited (CWPWF) Income Statement Analysis – Financial Results
- BD Multimedia SA (ALBDM.PA) Income Statement Analysis – Financial Results
- BioNeutra Global Corporation (BGACF) Income Statement Analysis – Financial Results
Kymera Therapeutics, Inc. (KYMR)
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | 0.00 |
| Cost of Revenue | 189.08M | 2.98M | 2.40M | 62.11M | 825.00K | 205.00K |
| Gross Profit | -110.49M | 43.85M | 70.44M | -28.07M | 2.11M | -205.00K |
| Gross Profit Ratio | -140.59% | 93.64% | 96.71% | -82.48% | 71.88% | 0.00% |
| Research & Development | 189.08M | 164.25M | 137.02M | 62.11M | 37.16M | 17.68M |
| General & Administrative | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Cost & Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Interest Income | 18.76M | 6.62M | 488.00K | 826.00K | 1.01M | 0.00 |
| Interest Expense | 196.00K | 176.00K | 175.00K | 115.00K | 46.00K | 16.00K |
| Depreciation & Amortization | 3.57M | 2.98M | 2.40M | 1.76M | 825.00K | 205.00K |
| EBITDA | -143.20M | -151.66M | -97.65M | -43.72M | -40.38M | -21.25M |
| EBITDA Ratio | -182.21% | -330.23% | -137.36% | -133.63% | -1,376.11% | 0.00% |
| Operating Income | -165.53M | -161.26M | -100.53M | -46.30M | -42.21M | -21.45M |
| Operating Income Ratio | -210.62% | -344.37% | -138.03% | -136.05% | -1,438.48% | 0.00% |
| Total Other Income/Expenses | 18.57M | 6.45M | 313.00K | 711.00K | 959.00K | -16.00K |
| Income Before Tax | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Income Before Tax Ratio | -186.99% | -330.60% | -137.60% | -133.96% | -1,405.79% | 0.00% |
| Income Tax Expense | 0.00 | -2.98M | -2.22M | -1.65M | 46.00K | 43.86K |
| Net Income | -146.96M | -151.83M | -98.00M | -43.95M | -41.29M | -21.47M |
| Net Income Ratio | -186.99% | -324.25% | -134.55% | -129.12% | -1,407.36% | 0.00% |
| EPS | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EPS Diluted | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| Weighted Avg Shares Out | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
| Weighted Avg Shares Out (Dil) | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin's lymphoma
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS)
Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with Rivian
Soros Fund Management, the investment firm founded by billionaire George Soros, took new positions or bulked up on IPOs and a number of tech names during the third quarter.
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
KT-474 showed evidence of robust target degradation and pathway inhibition with a favorable safety profile in healthy volunteers and patients
Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases
Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide short-term financial stability. Market sentiment is mixed, with high short interest...
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call...
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that the Company will participate at the following upcoming...
Source: https://incomestatements.info
Category: Stock Reports